podcast

#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

02.06.2026
Listen to the episode on your favorite platforms:
  • Apple Podcasts
  • Youtube
  • Spotify
  • Звук
  • Castbox
  • Pocket Casts
  • Stitcher
  • iHeart
  • PlayerFM
  • Overcast
  • Castro
  • RadioPublic

Jake Becraft is the CEO and co-founder of Strand Therapeutics, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.

This episode is brought to you by:

  • Helix Sleep premium mattresses: HelixSleep.com/Tim (20% off any purchase)
  • Incogni, which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: Incogni.com/Tim (use code TIM at checkout and get 60% off an annual plan)

Timestamps:

  • [] Start.
  • [] What Strand does.
  • [] The Boston dinner.
  • [] The image of a body riddled with cancer.
  • [] What stuck for the muggles in the pitch deck.
  • [] A good drug vs. a good product.
  • [] Tricking cancer into snitching on itself.
  • [] The abscopal effect.
  • [] Potency, specificity, and delivery.
  • [] First principles thinking.
  • [] The precipice of a revolution.
  • [] The thousand people in the room.
  • [] Psychedelic medicine as a cautionary tale.
  • [] What actually catches a policymaker’s attention.
  • [] Breakthrough vs. incremental.
  • [] What’s in it for the policymakers?
  • [] The 80/20 wish list.
  • [] Australia’s CTN system.
  • [] Sheep, psychedelics, and red-tape arbitrage.
  • [] China’s clinical-trial flywheel vs. slow-motion American loss.
  • [] The bicoastal biotech ethos.
  • [] Can the FDA actually pull this off?
  • [] The Sophie’s Choice of pharma development.
  • [] Lost arts of founder mode.
  • [] Rockets for tumors, T-cells, and beyond.
  • [] Viral in policy circles.
  • [] The Washington Post headline and the PickFu split test.
  • [] Solution-first storytelling.
  • [] RNA medicine and platform therapeutics.
  • [] Moderna’s 62 days.
  • [] Uber Eats and the de-risked launch.
  • [] CEO blockers.
  • [] Where’s biotech’s SpaceX moment?
  • [] Elon Musk betting black on the wheel.
  • [] AWS and the post-conviction / pre-consensus window.
  • [] COVID politicization.
  • [] Insulin, growth hormone, and the original platform story.
  • [] Biotech as pharma’s little brother.
  • [] More recent role models, Apple edition.
  • [] Art Levinson, Steve Jobs, and the biotech-tech crossover.
  • [] The iPhone as a delivery platform.
  • [] Spotify’s problem and the future of bespoke medicine.
  • [] Baby KJ and the limits of liver-only solutions.
  • [] Parting thoughts.

*

For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.

For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsors

Sign up for Tim’s email newsletter (5-Bullet Friday) at tim.blog/friday.

For transcripts of episodes, go to tim.blog/transcripts.

Discover Tim’s books: tim.blog/books.

Follow Tim:

Twitter: twitter.com/tferriss 

Instagram: instagram.com/timferriss

YouTube: youtube.com/timferriss

Facebook: facebook.com/timferriss 

LinkedIn: linkedin.com/in/timferriss

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.